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Abstract
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition
and Allergies (NDA) was asked to deliver a scientific opinion on the safety and suitability for use by
infants of follow-on formulae (FOF) based on cow’s milk intact protein with a protein content of at
least 1.6 g/100 kcal (rounded value) that meet otherwise the requirements of relevant EU legislation.
If the formula under evaluation is considered to be safe and suitable for use by infants, the NDA
Panel is also asked to advise on whether FOF based on goat’s milk intact protein, soy protein isolates
or protein hydrolysates are also safe and suitable for infants under the same conditions. The
Panel concludes that the use of FOF with a protein content of at least 1.6 g/100 kcal from either intact
cow’s milk protein or intact goat’s milk protein otherwise complying with the requirements of relevant
EU legislation is safe and suitable for healthy infants living in Europe with an intake of complementary
foods of a sufficient quality. This conclusion does not apply to infant formula (IF). The Panel also
concludes that the safety and suitability of FOF with a protein content of at least 1.6 g/100 kcal
manufactured from either protein hydrolysates or soy protein isolates cannot be established with the
available data. The same conclusion applies to IF. The NDA Panel endorsed a draft of this scientific
opinion on 14 December 2016 for public consultation. The draft document has been revised and
updated according to the comments received, where appropriate.
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Summary
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition
and Allergies (NDA) was asked to deliver a scientific opinion on the safety and suitability for use by
infants of follow-on formulae (FOF) based on cow’s milk intact protein with a protein content of at
least 1.6 g/100 kcal (rounded value) that meet otherwise the requirements of relevant European Union
(EU) legislation. If the formula under evaluation is considered to be safe and suitable for use by
infants, the NDA Panel is also asked to advise on whether FOF based on goat’s milk intact protein, soy
protein isolates or protein hydrolysates are also safe and suitable for infants under the same
conditions.
For the scientific assessment, the NDA Panel considered: (a) the dietary protein requirements of
infants in the second half of the first year of life, (b) the protein content of breast milk during the first year
of lactation, (c) dietary protein intake of infants in Europe from breast milk, formula and complementary
food (CF), (d) the overall contribution that a FOF with a protein content of 1.6 g/100 kcal could
make towards protein requirements in the target population, assuming an intake of CF of a sufficient
quality, following established feeding guidelines in Europe (e.g. from Member States), and (e) the
application submitted by the food business operator, including two intervention studies in healthy term
infants.
The Panel notes that:
a) population reference intakes (PRIs) of 8–9 g protein per day for girls and 9–10 g protein per
day for boys aged 6 months, and a PRI of 10–11 g protein per day for girls and 11–12 g
protein per day for boys aged 12 months have been established;
b) the mean content of true protein in breast milk by the end of the third month of lactation ranges
between 1.3 and 1.6 g/100 kcal, tends to decrease thereafter to about 1.1–1.4 g/100 kcal by
the end of the fourth month, corresponding to about 1.6 g/100 kcal of total protein The mean
total protein is about 1.1 g/100 mL (1.6 g/100 kcal) at 6 months of lactation and tends to
remain fairly stable thereafter;
c) the 5th and the 2.5th percentiles (P5th and P2.5th, respectively) of total protein intake in non-
breastfed infants aged 6–12 months living in Europe was around or above the PRI for protein
for that age group in all the studies and surveys available;
d) the P5th and P2.5th of total protein intake resulting from the consumption of FOF with a
protein content of 1.6 g/100 kcal would remain at about or above the PRI for protein for
infants aged 6–12 months who are not breastfed;
e) the two randomised, double-blind, controlled intervention studies provided by the applicant
showed no differences in growth patterns between healthy term infants who consumed formulae
with total protein contents of 1.61 g/100 kcal and 1.65 g/100 kcal from 3 months of age
onwards and infants who consumed formulae with total protein contents of 2.15 g/100 kcal
and 2.70 g/100 kcal, respectively. The control formula used in these studies contained
0.35 g/100 kcal (US study) and 0.90 g/100 kcal (Chile study) more protein than the current
minimum requirement for protein content of a FOF (1.8 g/100 kcal).
The Panel also notes that the studies submitted were not specifically designed to meet the
regulatory definitions for either infant formula (IF) or FOF laid down in Regulation (EU) No 609/20131,
and that the information provided in relation to the type and amount of CF was not sufficient to
calculate total energy and protein intake, nor the relative contribution of formulae and CF to total
energy and protein intake. Therefore, the Panel considers that these studies do not provide, on their
own, sufficient information to conclude on the safety and suitability of a FOF with a total protein
content of 1.6 g protein/100 kcal.
The Panel notes, however, that:
a) the true protein content of human milk tends to decrease with feeding time to about
1.1–1.4 g/100 kcal by the end of the fourth month of lactation, corresponding to about
1.6 g/100 kcal of total protein, and remains fairly stable thereafter;
1 Regulation (EU) No 609/2013 of the European Parliament and of the Council of 12 June 2013 on food intended for infants and
young children, food for special medical purposes, and total diet replacement for weight control and repealing Council Directive
92/52/EEC, Commission Directives 96/8/EC, 1999/21/EC, 2006/125/EC and 2006/141/EC, Directive 2009/39/EC of the
European Parliament and of the Council and Commission Regulations (EC) No 41/2009 and (EC) No 953/2009, OJ L 181,
29.6.2013, p. 35–56.
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b) the P5th and P2.5th of protein intake from all sources (breast milk, formula and CF) in
European infants between 6 and 12 months of age are at or above the PRI for protein for that
age group;
c) the P5th and P2.5th of protein intake from all sources (formula and CF) in European infants
between 6 and 12 months of age who are not breastfed would remain at or above the PRI for
protein for that age group by assuming a protein content of 1.6 g/100 kcal in all FOF;
d) the two human intervention studies provided by the applicant did not show an adverse impact
on growth resulting from the use of a formula containing about 1.6 g of protein/100 kcal as
compared to control formulae containing 2.15 or 2.70 g of protein/100 kcal or the breastfed
reference group.
Therefore, the Panel concludes that the use of FOF with a protein content of at least 1.6 g/100 kcal
from intact cow’s milk protein otherwise complying with the requirements of relevant EU legislation is
safe and suitable for healthy infants living in Europe with an intake of complementary foods of a
sufficient quality. This conclusion does not apply to IF.
On the basis of:
a) a previous evaluation by the Panel on the safety and suitability of goat’s milk protein as a
source of protein in IF and FOF (EFSA NDA Panel, 2012b), and
b) the Panel’s conclusions regarding the safety and suitability of FOF with a protein content of at
least 1.6 g/100 kcal from intact cow’s milk protein otherwise complying with the requirements
of relevant EU legislation,
the Panel concludes that the use of FOF with a protein content of at least 1.6 g/100 kcal from intact
goat’s milk protein otherwise complying with the requirements of relevant EU legislation is safe and
suitable for healthy infants living in Europe with an intake of complementary foods of a sufficient
quality. This conclusion does not apply to IF.
The Panel considers, however, that the safety and suitability of each FOF (and IF) manufactured
from protein hydrolysates have to be established by clinical evaluation in the target population (EFSA
NDA Panel, 2014). The Panel also considers that, given the higher minimum protein requirements
established for FOF (and IF) manufactured from soy protein isolates (i.e. 2.25 g/100 kcal) and the lack
of data available on the use of FOF from soy protein isolates in the target population, additional
studies are required to establish the safety and suitability of FOF manufactured from soy protein
isolates with a protein content of at least 1.6 g/100 kcal. Therefore, the Panel concludes that the
safety and suitability of FOF with a protein content of at least 1.6 g/100 kcal manufactured from either
protein hydrolysates or soy protein isolates cannot be established with the available data. The same
conclusion applies to IF.
Safety and suitability of FOF with a protein content of at least 1.6 g/100 kcal
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1. Introduction
1.1. Background and Terms of Reference as provided by the European
Commission
1.1.1. Background
Commission Directive 2006/141/EC2 lays down requirements for infant formulae and follow-on
formulae placed on the market in the European Union (EU). Among others, it establishes that follow-
on formula manufactured from cows’ milk intact protein shall contain at least 1.8 g protein/100 kcal
(Annex II, point 2.1).
Commission delegated Regulation (EU) 2016/1273 revises the rules of Commission Directive 2006/
141/EC and shall repeal and replace the Directive from 22 February 2020. Annex II, point 2.1 of the
delegated Regulation maintains the minimum protein content of follow-on formula manufactured from
cows’ milk intact protein at 1.8 g/100 kcal.
The Commission has received a request from a food business operator for placing on the market a
follow-on formula based on cow’s milk intact protein with a protein content of at least 1.61 g/100 kcal,
which is below the permitted levels of Directive 2006/141/EC and delegated Regulation (EU) 2016/127.
In order to consider such request, the Commission needs to obtain the advice of the European Food
Safety Authority (EFSA) and has asked the food business operator to send the scientific dossier to the
Authority for assessment.
1.1.2. Terms of Reference
In accordance with Article 29 of Regulation (EC) No 178/20024, the European Commission requests
EFSA to issue an opinion on the safety and suitability for use by infants of a follow-on formula (FOF)
based on cow’s milk intact protein with a protein content of at least 1.61 g/100 kcal.
If the formula under evaluation is considered to be safe and suitable for use by infants, EFSA is
asked to advise whether a level of at least 1.61 g protein/100 kcal would be applicable to all FOFs. If
this is not the case, the Authority is asked to advise on the specific criteria that need to be satisfied for
the safety and suitability of such formulae to be demonstrated.
1.2. Interpretation of the Terms of Reference
The Panel interprets the terms of reference provided by the European Commission in the context of
the background information given and the application submitted. The Panel understands that the
European Commission seeks advice on:
a) whether a FOF based on cow’s milk intact protein with a minimum protein content of 1.6 g/100 kcal
(rounded value) is safe and suitable for infants provided that it meets otherwise the requirements5
of relevant EU legislation,6 and if so
b) whether FOF based on goat’s milk intact protein, soy protein isolates or protein hydrolysates
with a minimum protein content of 1.6 g/100 kcal (rounded value) are also safe and suitable
for infants provided that they meet otherwise the requirements of relevant EU legislation.
2 Commission Directive 2006/141/EC of 22 December 2006 on infant formulae and follow-on formulae and amending Directive
1999/21/EC, OJ L 401, 30.12.2006, p. 1.
3 Commission Delegated Regulation (EU) 2016/127 of 25 September 2015 supplementing Regulation (EU) No 609/2013 of the
European Parliament and of the Council as regards the specific compositional and information requirements for infant formula
and follow-on formula and as regards requirements on information relating to infant and young child feeding, OJ L 25,
2.2.2016, p. 1.
4 Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general
principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in
matters of food safety, OJ L 31, 1.2.2002, p. 1.
5 Including the requirements with respect to the amino acid profile.
6 Directive 2006/141/EC to be replaced by delegated Regulation (EU) 2016/127.
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2. Data and methodologies
2.1. Data
EFSA was provided with a dossier related to a FOF based on cow’s milk intact protein containing a
minimum of 1.61 g protein/100 kcal but otherwise complying with the compositional criteria laid down
in Directive 2006/141/EC. The dossier includes two intervention studies in infants, named ‘US study’
(Hayes and Northington, 2014; unpublished study report #1; published as Ziegler et al., 2015), and
‘Chile study’ (Yao, 2014; unpublished study report #2; published as Inostroza et al., 2014). The dossier
was supplemented, upon request of EFSA, with additional information provided by the applicant on 28
June 2016 and on 29 September 2016. The intervention studies provided in the dossier were designed
to assess the growth pattern of infants receiving a formula with standard protein content for the first
three months of life and thereafter a formula with a protein content which is lower than currently
authorised. These studies aimed to investigate whether lower protein content in formula to be fed from
3 to 12 months of age, in line with the decrease in the protein content of breast milk during that
feeding period, would lead to growth rates closer to those of breastfed infants, as compared to infants
fed a ‘standard’ formula.
The Panel will also take into account in the current assessment its previous opinions on Dietary
Reference Values for protein (EFSA NDA Panel, 2012a), on nutrient requirements and dietary intake of
infants and young children in Europe (EFSA NDA Panel, 2013), and on the essential composition of IF
and FOF (EFSA NDA Panel, 2014), as well as data on the protein content of breast milk.
2.2. Methodologies
As outlined in the Panel’s previous opinion on the essential composition of infant formula (IF) and
FOF (EFSA NDA Panel, 2014), the minimum amounts of nutrients in formulae, including protein, should
be based on generally accepted scientific evidence. While for IF compositional requirements may be
based on the energy and nutrient requirements of infants and on the results of intervention studies in
the target population in which the formula is the only source of energy and nutrients, evidence for
proposing compositional requirements for foods which are not the sole source of energy and nutrients,
such as FOF, is less strong, as other foods contribute to nutrient and energy intake in variable
amounts. In its previous opinion, when proposing compositional requirements for FOF, the
Panel assumed that complementary food (CF) would compensate for the higher energy and nutrient
requirements of older infants and for the lower formula intake during that period. This is based on the
assumption that infants in the target population have access to CF of a sufficient quality, following
established feeding guidelines in Europe (e.g. from Member States).
For the present assessment of whether a FOF based on cow’s milk intact protein with a protein
content of at least 1.6 g/100 kcal (rounded value) is safe and suitable for infants provided that it
meets otherwise the requirements5 of relevant EU legislation,6 the Panel will consider:
a) dietary protein requirements of infants in the second half of the first year of life;
b) protein content in breast milk during the first year of lactation;
c) dietary protein intake of infants in Europe from breast milk, formula and CF;
d) the overall contribution that a FOF with a protein content of 1.6 g/100 kcal could make
towards protein requirements in the target population, assuming an intake of CF of a sufficient
quality, following established feeding guidelines in Europe (e.g. from Member States);
e) the application submitted by the food business operator, including two intervention studies in
healthy term infants.
The evaluation of the intervention studies provided by the food business operator will follow the
general principles for the assessment of a modification of the composition of IFs or FOFs outside the
established standards as laid down by the Scientific Committee on Food (SCF, 2003). In addition,
the recommendations for the assessment of the safety and suitability of formulae for term infants of
the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) (Aggett
et al., 2001), of the Committee on the Evaluation of the Addition of Ingredients New to Infant Formula
of the Food and Nutrition Board of the United States (US) Institute of Medicine (IoM, 2004) and of the
American Academy of Pediatrics (AAP, 1988), will be taken into account.
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3. Assessment
3.1. Dietary protein requirements of infants in the second half of the
first year of life
Dietary protein is an essential component of the diet, supplying the body with nitrogen (N) and
amino acids as well as other non-protein metabolically active nitrogen-containing substances. The
protein requirement of infants and young children comprises two components, the maintenance
requirement and the growth requirement (EFSA NDA Panel, 2012a). In its previous opinion, the
Panel established an average maintenance requirement of 0.66 g protein/kg body weight per day
(105 mg N/kg body weight per day) for infants and young children aged from 6 to < 36 months,
which was derived from nitrogen balance studies in adults. The average protein requirement for
growth was estimated from average daily rates of protein deposition calculated from studies on whole-
body potassium deposition, and adjusted by an efficiency of utilisation of dietary protein for growth of
58%. Together, these amounts constitute an average requirement (AR), to which 1.96 standard
deviations were added to derive a population reference intake (PRI).
Using the 50th percentile of the reference body weights (kg) of European children (van Buuren
et al., 2012), a PRI of 9 g protein per day for girls and 10 g protein per day for boys aged 6 months
and a PRI of 11 g protein per day for girls and 12 g protein per day for boys aged 12 months were
established (EFSA NDA Panel, 2012a). The use of the 50th percentile of the WHO Growth Standards
(WHO Multicentre Growth Reference Study Group, 2006) as reference weights resulted in slightly lower
PRIs for protein (in g/day) for the same age and sex groups, i.e. 8 g protein per day for girls and 9 g
protein per day for boys aged 6 months and a PRI of 10 g protein per day for girls and 11 g protein
per day for boys aged 12 months (EFSA NDA Panel, 2013).
3.2. Protein content of breast milk during the first year of lactation
Estimating the true protein content of breast milk is challenging because of the non-protein
nitrogen fraction contained in it. Total nitrogen in human milk represents both protein, about 75%,
and non-protein nitrogen, which is made up of urea (up to 50% of the non-protein nitrogen), amino
acids and other nitrogen-containing compounds (SCF, 2003; FAO/WHO/UNU, 2007). The amount of
nitrogen used by infants for protein synthesis is likely to include that from true protein, free amino
acids and small peptides, and a proportion of urea nitrogen. Therefore, the amount of nitrogen in
breast milk used for protein synthesis by infants is between the true protein content and the crude
(total) protein calculated from total nitrogen.
In a meta-analysis of 21 studies reporting on energy and macronutrient composition of breast milk
from mothers of healthy singleton infants born at term and who were exclusively breast fed at the
time of breast milk sampling (Hester et al., 2012), crude (total) protein content expressed as mean
(range) was 2.5 (1.4–6.5) g/100 mL (3.8 (2.2–10.0) g/100 kcal, n = 433) for colostrum (1–5 days);
1.7 (1.3–2.5) g/100 mL (2.6 (2.0–3.8) g/100 kcal, n = 308) for transitional milk (6–14 days); and 1.3
(0.8–2.1) g/100 mL (2.0 (1.2–3.2) g/100 kcal, n = 415) for mature human milk (> 14 days).
A meta-analysis of 41 published studies reports on the composition of preterm (26 studies, 843
mothers) and term (30 studies, 2,299 mothers) breast milk during the first 12 weeks of lactation
(Gidrewicz and Fenton, 2014). Energy was estimated in 11 studies using bomb calorimetry, and in five
studies by calculation using values for the energy contributions from fat, protein and carbohydrate.
Protein was estimated based on total nitrogen in 23 studies and as a true protein estimate in 15
studies. Data on mean energy and protein content of breast milk from mothers of term infants by
week of lactation is shown in Table 1.
Safety and suitability of FOF with a protein content of at least 1.6 g/100 kcal
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The true protein content of breast milk gradually decreased from the first week of lactation, being
about 1.0 g/100 mL (corresponding to about 1.5–1.6 g/100 kcal) by the third month, which
corresponds to 1.2 g/100 mL (1.8–1.9 g/100 kcal) of total protein. The amount of total protein
(calculated from total nitrogen) in the second week of lactation was comparable to that reported for
transitional breast milk (6–14 days) in the meta-analysis by Hester et al. (2012).
Table 2 shows the energy (calculated) and the interval from birth according to the true protein
content (measured by infrared spectroscopy) of breast milk samples (n = 2,554) donated by 224
mothers of mostly term infants to a milk bank in Denmark (Michaelsen et al., 1990). The mean true
protein content of all samples combined was 0.9 g/100 mL.
The mean interval from birth gradually decreased with the increasing content of protein in breast
milk. It was 3–4 weeks for samples containing ≥ 1.3 g/100 mL and 19–20 weeks for samples
containing < 0.7 g/100 mL. The mean interval from birth was 11–12 weeks for samples containing
0.9–1.09 g/100 mL, which is consistent with the true protein content of breast milk by the third month
of lactation (1.0 g/100 mL) reported by Gidrewicz and Fenton (2014).
A meta-analysis of 26 studies reporting on the protein content and protein composition of breast
milk during the first year of life has also been published (L€onnerdal et al., 2017). In this meta-analysis,
only studies reporting on true protein data (total nitrogen – non-protein nitrogen, with a 6.25
conversion factor) obtained using the Kjeldahl, Lowry, Biuret and bicinchoninic acid kits were included.
The 26 articles provided 130 data points, 70% of which were for samples obtained during the first
three weeks of lactation. The Panel notes that the number of breast milk samples analysed in studies
reporting on the protein content of breast milk during the first year of lactation is low (e.g. Allen et al.,
1991; Mitoulas et al., 2002).
Data on the true protein content of breast milk by month of lactation is reported as a median of
2.06 g/100 mL for colostrum (0–5 days after delivery), of 1.57 g/100 mL for mature milk (16–30 days)
and of 1.1 g/100 mL for breast milk samples from 3 to 12 months of lactation on average. A linear
regression analysis is provided in a figure considering all samples (mean and 95% CI of true protein
content over the first year). The Panel notes that the mean true protein content of breast milk was
about 1.4 g/100 mL at 3 months, 1.2 g/100 mL at 4 months, 1.1 g/100 mL at 6 months and about
Table 1: Mean energy and protein content of breast milk from mothers of term infants by week of
lactation(a)
Mean energy (SD)
(kcal/100 mL)
Mean protein (SD)
(g/100 mL)
Mean protein (SD)
(g/100 kcal)
Time
Bomb
calorimetry
Calculated
True
protein
Protein
calculated
from total
nitrogen
True protein
Protein
calculated
from total
nitrogen
4–7 days 66 (9) 68 (10) 1.6 (0.3) 2.0 (0.5) 2.4 (0.5) 2.9 (0.7)–3.0 (0.8)
2 week 66 (9) – 1.3 (0.2) 1.8 (0.4) 2.0 (0.3) 2.7 (0.63)
3–4 week 66 (8) 70 (9) 1.1 (0.2) 1.5 (0.3) 1.6 (0.3)–1.7 (0.3) 2.1 (0.4)–2.3 (0.5)
5–6 week 63 (7) – 1.0 (0.1) 1.1 (0.2) 1.6 (0.2) 1.7 (0.3)
7–9 week 63 (7) 69 (10) 0.9 (0.1) 1.3 (0.2) 1.3–1.4 (0.2) 2.1 (0.3)
10–12 week 63 (8) 68 (9) 1.0 (0.1) 1.2 (0.2) 1.5–1.6 (0.2) 1.8 (0.3)–1.9 (0.3)
(a): Adapted from Gidrewicz and Fenton (2014).
Table 2: Time interval from birth according to the true protein content of breast milk(a)
True protein
(g/100 mL)
Mean interval from
birth (weeks)
Mean (SD) energy
(kcal/100 mL)
True protein
(g/100 kcal)
No. of
samples
≥ 1.3 3–4 74.7 (9.8) ≥ 1.7 70
1.1–1.29 6–7 71.4 (9.8) 1.5–1.8 193
0.9–1.09 11–12 67.4 (9.8) 1.3–1.6 572
0.7–0.89 15–16 64.6 (9.8) 1.1–1.4 800
< 0.7 19–20 64.2 (9.3) < 1.1 108
(a): Adapted from Michaelsen et al. (1990).
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1.0 g/100 mL at 8–12 months of lactation. The Panel also notes that the energy content of breast milk
is not reported, and thus the true protein content per 100 kcal cannot be calculated.
In the context of the DARLING study, Nommsen et al. (1991) assessed the composition of breast
milk in samples taken at 3, 6, 9 and 12 months of lactation in healthy mothers of term infants. The
gross energy content and the total protein content of the breast milk samples are given in Table 3.
Protein was analysed using a modified Lowry assay with bovine serum albumin as the standard, a
method which tends to result in slightly elevated values for total protein (Nommsen et al., 1991).
The mean total protein at three months of lactation (1.2 g/100 mL, 1.7 g/100 kcal) is comparable
to the total protein content for that time period in the meta-analysis by Gidrewicz and Fenton (2014)
(1.2 g/100 mL, 1.8 g/100 kcal). The mean total protein was 1.1 g/100 mL (1.6 g/100 kcal) at
6 months of lactation and remained fairly stable until the 12th month, which is consistent with the
stable content of true protein in breast milk from the 6th to the 12th month of lactation reported in
the meta-analysis by L€onnerdal et al. (2017).
The Panel notes that the mean content of true protein in breast milk by the end of the third
month of lactation ranges between 1.3 and 1.6 g/100 kcal, tends to decrease thereafter to about
1.1–1.4 g/100 kcal by the end of the fourth month, corresponding to about 1.6–1.7 g/100 kcal of total
protein. The mean total protein is about 1.1 g/100 mL (1.6 g/100 kcal) at 6 months of lactation and
tends to remain fairly stable thereafter.
3.3. Dietary protein intake of infants in Europe
Data on mean energy and protein intake in infants living in Europe were gathered from published
studies (Table 4). Details about the dietary data collection and on the assessment of breast milk
intake are given in Table 5.
Data on mean energy and protein intake in infants living in Europe were also gathered form dietary
surveys for which sufficient data were available in the EFSA Comprehensive European Food
Consumption Database (Table 6).7
From the dietary surveys available in the EFSA Comprehensive European Food Consumption
Database, mean energy and protein intake from formula and from CF in non-breastfed infants, and
from CF only in (exclusively or partially) breastfed infants were also calculated (Table 7). Mean energy
and protein intake by food group in non-breastfed infants are given in Tables 8 (for infants 4 to
< 6 months of age) and 9 (for infants aged ≥ 6 to 12 months).
Table 3: Gross energy and total protein content of breast milk during the first year of lactation(a)
Month of
lactation
n
Mean (SD) gross energy
(kcal/100 mL)
Mean (SD) total protein
(g/100 mL)
Mean (SD) total protein
(g/100 kcal)
3 58 69.7 (97) 1.2 (0.2) 1.7 (1.5)
6 45 70.7 (92) 1.1 (0.2) 1.6 (1.6)
9 28 70.9 (74) 1.2 (0.8) 1.6 (10.8)
12 21 70.6 (110) 1.2 (0.2) 1.7 (1.3)
(a): Adapted from Nommsen et al. (1991).
7 Details about the dietary surveys included in the EFSA Comprehensive Database are available at: https://dwh.efsa.europa.eu/
bi/asp/Main.aspx?rwtrep=001
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Mean protein intakes from all sources were above the PRI for protein in all surveys from the EFSA
Comprehensive Database for both breastfed and formula-fed infants aged 6–12 months (Table 6).
Mean protein intake from all sources were also reported in published studies which accurately
estimated breast milk intake (by weighing the infant before and after each breast milk meal) and/or
which used more accurate methods for dietary assessment (3- or 4-day weighted dietary records). At
4 months of age, the lowest mean protein intake (12 g/day) was reported for infants exclusively
breastfed in the ALSPAC cohort. Mean protein intakes were slightly higher (13 g/day) in breastfed
infants who had already received some solid food. The lowest mean protein intake (16.3 g/day) for
infants aged 6 months or older was reported in a German cohort (DONALD study), in which the
proportion of breastfed infants was the highest (48%) among all the studies available (Table 4).
Mean protein intakes from all sources were above the PRI for protein for infants aged 6–12 months in
all the studies.
In the dietary surveys for which data on (exclusively or partially) breastfed infants and formula-fed
infants were available separately (Table 6), mean protein intakes were systematically higher in
formula-fed infants than in breastfed infants, as previously reported by others (Heinig et al., 1993).
Breast milk was assumed to contain from 1.4 to 1.9 g of protein/100 kcal, depending on the survey.
The lower mean protein intake reported for Bulgarian infants could be explained in part by the
assumed lower protein content in breast milk (1.4 g/100 kcal). The protein content of formula ranged
from 2.1 to 2.7 g of protein/100 kcal, depending on the survey and age category (Table 7). This is
higher than the minimum protein content allowed by EU legislation (Directive 2006/141/EC and
Commission delegated Regulation (EU) 2016/127) for (infant and follow-on) formula manufactured
from intact cow’s or goat’s milk proteins (1.8 g/100 kcal).
In breastfed infants, mean protein intake from CF ranged between 3.7 and 6.0 g/day in infants
aged 4 to < 6 months, and was already well beyond the PRI for protein in infants aged 6–12 months
(about 17 g/day). In formula-fed infants aged 4–6 months, mean protein intake from formula ranged
from 6.5 to 12.0 g/day, while mean protein intakes from CF were about 6 g/day. In Bulgaria, where
mean protein intake from formula was the lowest (6.5 g/day), mean protein intake from CF was much
higher (9.8 g/day), mostly coming from cow’s milk and dairy products other than formula (Table 8).
This is due to a replacement of IF with cow’s milk (rather than with FOF) at the time of the
introduction of CF. In formula-fed infants aged 6–12 months, mean protein intakes from CF were at or
above the PRI in all countries. The contribution of formula to total protein intake varied widely, being
lower in countries (Bulgaria and Denmark) with the highest protein intake from cow’s milk and dairy
products and from meat and meat products (Table 9).
Whenever the data available allowed doing so, the 5th and the 2.5th percentiles (P5th and P2.5th,
respectively) of protein intake were calculated by assuming a normal distribution of protein intake data
(Table 4) or extracted from individual data (Table 6). Otherwise, IQRs or 95% CI were considered
(Table 4). The Panel notes that the P5th and P2.5th of total protein intake in non-breastfed infants
aged 6–12 months was around or above the PRI for protein for that age group in all the studies
(Table 4) and surveys (Table 6) available.
3.4. Contribution that a FOF with a protein content of at least
1.6 g/100 kcal could make towards protein requirements in the
target population
Consumption of a FOF with a protein content of about 1.6 g/100 kcal would provide about 9 g of
protein per day in the first months of complementary feeding (assuming an intake of about 500 mL/day)
and about 4.5 g of protein per day (assuming an intake of about 250 mL/day) by the end of the first year
of life. This is about 1 g and 0.5 g of protein less than the estimated intake from a formula containing a
minimum of 1.8 g/100 kcal, as currently authorised. The Panel notes, however, that the protein content
of (infant and follow-on) formula in the European surveys available (from 2.1 to 2.7 g of protein/100 kcal,
Table 7) was higher than the minimum authorised.
Using individual data from the three surveys which were available in the EFSA Comprehensive Food
Consumption Database, total protein intake in non-breastfed infants aged 6–12 months was
recalculated by assuming that: (a) all FOF consumed by the infants contained 1.6 g of protein/
100 kcal; (b) the energy content of the individual FOFs did not change; (c) protein intake from other
sources (IF, CF) did not change. The mean, P5th and P2.5th of total protein intake under these
conditions are shown in Table 10.
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As expected, total protein intakes resulting from the consumption of FOF with a protein content of
1.6 g/100 kcal would be lower than those reported in the original surveys (Table 6). The Panel notes,
however, that the P5th and P2.5th of total protein intake would remain at about or above the PRI for
protein for infants aged 6–12 months.
3.5. Application submitted by the food business operator
The applicant provided two human intervention studies aiming to investigate whether protein
content in formula to be fed from 3 to 12 months of age that is closer to the protein content of breast
milk during that feeding period would lead to growth rates more in line with those of breastfed infants,
as compared to infants fed a ‘standard’ formula.
3.5.1. Composition of the formulae used in the two human intervention studies
The formulae investigated in the US and Chile studies contain a minimum of 1.61 g protein/
100 kcal (1.61 and 1.65 g/100 kcal, respectively), calculated from total nitrogen analysis by the
Kjeldahl method and using a nitrogen conversion factor of 6.25. The protein source is based on intact
proteins derived from skimmed milk and a proprietary preparation of demineralised whey. The
demineralised whey is obtained from modified caseinoglycomacropeptide (CGMP)-reduced sweet whey
produced using a patented process (Patent No PCT/EP1998/003176). The whey preparation used in
the formula has a CGMP content which is reduced by at least 85%. The whey protein-to-casein ratio of
the final product is 60:40. The applicant indicated that the protein sources have been used in other
FOF currently marketed by the applicant, and that the use of CGMP-reduced sweet whey has allowed
for a lower protein content of the FOF, while still meeting the requirements of Directive 2006/141/EC
with respect to the amino acid pattern. The energy content and the amount of carbohydrates, fat,
vitamins and minerals also comply with the compositional requirements laid down in Directive 2006/
141/EC.
The macronutrient composition of the intervention and control formulae used in the US and the
Chile studies are outlined in Table 11.
Table 10: Protein intake in European non-breastfed infants aged 6–12 months, assuming a protein
content of FOF of 1.6 g/100 kcal
Country N
Mean energy intake
(kcal/day)
Mean protein
intake (g/day)
P5th of protein
intake (g/day)
P2.5th of protein
intake (g/days)
Bulgaria 343 859 27.2 13.7 11.9
Denmark 473 933 29.4 15.8 13.8
UK 1,029 790 24.4 12.6 11.2
Table 11: Macronutrient composition of study formulae in comparison to the compositional
requirements for FOF manufactured from cow’s or goat’s milk proteins as laid down in
Directive 2006/141/EC
Unit
Directive
2006/141/EC
US study Chile study
Intervention Control Intervention Control
Energy kcal/100 mL 60–70 67.2 64.6 62.8 65.6
Protein g/100 kcal 1.8–3.5 1.61 2.15 1.65 2.70
Fat g/100 kcal 4.0–6.0 5.46 5.21 5.30 5.03
Carbohydrates g/100 kcal 9.0–14.0 11.10 11.13 11.41 10.98
Cyst(e)ine mg/100 kcal 38 28 38 28 46
Histidine mg/100 kcal 40 40 49 39 64
Isoleucine mg/100 kcal 90 95 125 100 166
Leucine mg/100 kcal 166 166 222 180 298
Lysine mg/100 kcal 113 132 185 142 234
Methionine mg/100 kcal 23 33 46 42 69
Phenylalanine mg/100 kcal 83 103 88 108 179
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The applicant states that the tyrosine and phenylalanine content (calculated as sum) and
tryptophan content in the intervention and control formulae of the US study were slightly lower than
required by Directive 2006/141/EC, and that the histidine content in the intervention formula of the
Chile study was slightly lower than required by Directive 2006/141/EC, but that the final marketed
product will comply with the specifications laid down in the Directive.
In the Chile study, the intervention formula also contained 2 9 107 colony forming units (CFU)
Bifidobacterium lactis (CNCM I-3446) and 2 9 107 CFU Lactobacillus rhamnosus (CGMCC 1.3724) per
gram of powder formula, while the control formula did not contain these bacteria.
The intervention formulae in both studies had a whey protein-to-casein ratio of 60:40.
3.5.2. Human intervention studies
The two randomised, double-blind, controlled intervention studies were conducted in Chile
(Inostroza et al., 2014) and in the US (Ziegler et al., 2015). These studies assessed growth rates in
healthy term infants who consumed (low-protein, intervention) formulae with protein contents of
1.61 g/100 kcal (n = 97) (US study) and 1.65 g/100 kcal (n = 89) (Chile study) from 3 months of
age onwards, against those of infants who consumed (control) formulae with protein contents
of 2.15 g/100 kcal (n = 97) and 2.70 g/100 kcal (n = 87), respectively, and against those of a
breastfed reference group (n = 76 and n = 112, respectively). In the Chile study, only infants from
overweight and obese mothers were recruited.
In both studies, the primary outcome was weight gain between 3 and 6 months of age. Secondary
outcomes included, among others, weight gain at time points beyond 6 months of age, weight
changes, changes in length and head circumference, and changes in serum albumin and blood urea
nitrogen (BUN). Adverse events were registered.
Statistical analyses were conducted in completers and per protocol (PP) in both studies. In the US
study, 10 infants in the intervention group, 10 infants in the control group and 7 infants in the
breastfed reference group discontinued the study. The numbers in the Chile study were 23, 11 and 11,
respectively. Reasons for withdrawal were provided.
Despite the original protocols foreseeing exclusive formula or breastfeeding up to the age of
6 months and the introduction of CF thereafter (control formula was allowed from 6 to 12 months to
the breastfed reference groups, if desired), small amounts of CF were provided to some infants from
around 4 months of age onwards. In the US study, a total of nine infants consumed > 4 teaspoons of
CF per day before the age of 6 months and were excluded from the PP analysis. In the Chile study, CF
in amounts > 4 teaspoons per day were introduced before 6 months of age in 66 infants (28 in the
intervention, 24 in the control and 14 in the breastfed reference group), who were not excluded from
the statistical analysis. In the breastfed reference group, one formula feeding per day was allowed
from 3 months of age onwards in the Chile study. Supplemental formula feeding at parent’s discretion
in the US study (control formula) and discontinuation of breastfeeding at mother’s discretion in the
Chile study (commercially available formula with a protein content of 2.4 g/100 kcal and energy
content of 67 kcal/100 mL) were allowed after 6 months.
Unit
Directive
2006/141/EC
US study Chile study
Intervention Control Intervention Control
Threonine mg/100 kcal 77 94 141 84 137
Tryptophan mg/100 kcal 32 31 31 34 57
Tyrosine mg/100 kcal 76 52 68 69 113
Valine mg/100 kcal 88 94 137 102 168
Methionine +
Cyst(e)ine
mg/100 kcal 61(a) 61 84 70 115
ratio 1.2 1.2 1.5 1.5
Tyrosine +
Phenylalanine
mg/100 kcal 159(b) 155 156 177 292
ratio 0.5 0.8 0.6 0.6
(a): The concentrations of cyst(e)ine and methionine may be added together if the methionine:cyst(e)ine-ratio is not > 3.
(b): The concentrations of tyrosine and phenylalanine may be added together if the tyrosine:phenylalanine-ratio is not > 2.
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The information provided in these studies did not allow the calculation of energy and protein intake
from CF at any time point, and thus of the total energy and protein intake at time points in which
infants consumed CF (4–12 months in the Chile study and 6–12 months in the US study).
Mean daily energy and protein intake from formula at different time points in the US and Chile
studies are given in Table 12.
The mean volume of formula consumed by infants did not differ significantly between the low
protein and the control groups at any time point in any of the studies. In this context, mean energy
intake from formula was comparable between the two formula groups while mean protein intake was
systematically higher in the control formula vs the low-protein formula groups in both studies, as per
study design. The Panel notes that the mean volume intake of formula in the low-protein formula and
control formula groups in both studies at 9 and 12 months of age was high.
The results of anthropometric measurements in the low-protein formula, control formula and
breastfed reference groups in both studies are given in Appendices A–D. In both studies, weight gain
(in g/day) was somewhat lower in the infants consuming the low protein formula than in infants
consuming the control formula for the time period 3–6 and 6–12 months of age, but this difference
only reached statistical significance for weight gain between 3 and 6 months in the Chile study. Other
anthropometric measures (i.e. weight, length and head circumference at different time points in
absolute values and as change from baseline) generally followed this pattern in both studies, although
statistically significant differences between groups were not detected at any time point.
In the US study, both formula groups showed statistically significantly higher weight gain and
higher weight and length in absolute values at different time points as compared to the breastfed
reference group. In the Chile study, the low-protein formula group and the breastfed reference group
Table 12: Mean daily energy and protein intake from formula at different time points in the US and
Chile studies
n
Mean (SD) volume
intake (mL/day)
Mean (SD) energy
intake (kcal/day)
Mean (SD) protein
intake (g/day)
US Study
4 months
Low-protein formula 83 905 (216) 608 (145) 9.8 (2.3)
Control formula 85 894 (180) 578 (116) 12.4 (2.5)
6 months
Low-protein formula 83 917 (232) 616 (156) 9.9 (2.5)
Control formula 84 902 (184) 583 (119) 12.5 (2.6)
8 months
Low-protein formula 80 850 (208) 571 (140) 9.2 (2.3)
Control formula 82 857 (179) 554 (116) 11.9 (2.5)
12 months
Low-protein formula 76 719 (239) 483 (161) 7.8 (2.6)
Control formula 78 725 (241) 468 (156) 10.1 (3.3)
Chile study
4 months
Low-protein formula 75 820 (268) 515 (168) 8.5 (2.8)
Control formula 80 868 (228) 569 (150) 15.4 (4.0)
6 months
Low-protein formula 62 980 (248) 615 (156) 10.2 (2.6)
Control formula 74 957 (172) 628 (113) 17.0 (3.0)
9 months
Low-protein formula 55 896 (256) 563 (161) 9.3 (2.7)
Control formula 64 869 (242) 570 (159) 15.4 (4.3)
12 months
Low-protein formula 47 854 (324) 536 (203) 8.8 (3.4)
Control formula 63 747 (217) 490 (142) 13.2 (3.8)
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did not differ significantly in weight gain, weight and length. The concentrations of serum albumin and
BUN remained within the normal range in all groups during the intervention in both studies. Reported
adverse events were similar in the intervention and control groups.
The Panel notes that, in both studies, no differences in growth patterns were observed between
infants in the control vs the low-protein formulae, including the time period of 3–6 months of age
when the formula was fed almost exclusively, except for a lower weight gain in the low-protein formula
group (time period 3–6 months) in the Chile study. In the US study, growth was higher in the low-
protein groups as compared to the breastfed reference group, whereas in the Chile study, infants in
the low-protein formula group had a similar growth pattern to breastfed infants. Mean weight-for-age
z-scores were, at all ages, at or above the median of WHO Growth Standards. The control formula
used in these studies contained 0.35 g/100 kcal (US study) and 0.90 g/100 kcal (Chile study) more
protein than the current minimum requirement for protein content of a FOF (1.8 g/100 kcal). In both
studies, at all-time points, the difference in mean protein intake from formula between the control
formula group and the low-protein formula group was about 3 g/day or greater.
The Panel also notes that the studies submitted were not specifically designed to meet the
regulatory definitions for either IF or FOF laid down in Regulation (EU) No 609/20131, and that the
information provided in relation to the type and amount of CF was not sufficient to calculate total
energy and protein intake, nor the relative contribution of formulae and CF to total energy and
protein intake. Therefore, the Panel considers that these studies do not provide, on their own,
sufficient information to conclude on the safety and suitability of a FOF with a protein content of 1.6 g
protein/100 kcal.
3.6. Comparison between the human intervention studies provided and
European dietary surveys with respect to mean energy and protein
intake from formula and complementary food in the target
population
In the European surveys which allowed calculation of mean energy and protein intake from both
(infant and follow-on) formula and CF in formula-fed infants, the protein content of formula was
between 2.1 and 2.7 g/100 kcal (Table 7). The lower end is close to the protein content of the control
formula used in the US study (2.15 g/100 kcal) and the upper end is close to the protein content of
the control formula used in the Chile study (2.70 g/100 kcal). Mean energy and protein intakes from
formula were, however, lower in infants aged 4 to < 6 months in the European surveys than in infants
at 4 months of age in the two formula groups (low protein and control) in both intervention studies
(US and Chile studies). In infants aged 6–12 months, mean energy and protein intakes from formula in
the European surveys were about half (or lower) than in the US and Chile studies. This suggests that
the contribution of formula (vs CF) to total protein intake in the target population (infants at the time
of the introduction of complementary feeding and up to 12 months of age) may be lower in Europe
than in the intervention studies provided. Therefore, the impact on total protein intake of lowering the
protein content of a follow-on formula to about 1.6 g/100 kcal would also be lower in Europe.
However, direct comparisons regarding total energy and protein intake and energy and protein intake
from CF between the European surveys and the intervention studies provided cannot be made.
4. Conclusions
4.1. On the safety and suitability for use by infants of FOF with a protein
content of at least 1.6 g/100 kcal from intact cow’s milk protein
otherwise complying with the requirements of relevant EU
legislation
The Panel considers that the two intervention studies provided by the applicant do not provide, on
their own, sufficient information to conclude on the safety and suitability of FOF with a total protein
content of 1.6 g protein/100 kcal.
The Panel notes, however, that:
a) the true protein content of human milk tends to decrease with feeding time to about
1.1–1.4 g/100 kcal by the end of the fourth month of lactation, corresponding to about
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1.6–1.7 g/100 kcal of total protein. The mean total protein is about 1.1 g/100 mL (1.6 g/100 kcal)
at 6 months of lactation and tends to remain fairly stable thereafter;
b) the P5th and P2.5th of protein intake from all sources (breast milk, formula and CF) in European
infants between 6 and 12 months of age are at or above the PRI for protein for that age group;
c) the P5th and P2.5th of protein intake from all sources (formula and CF) in European infants
between 6 and 12 months of age who are not breastfed would remain at or above the PRI for
protein for that age group by assuming a protein content of 1.6 g/100 kcal in all FOF; and
d) the two human intervention studies provided by the applicant did not show an adverse impact
on growth resulting from the use of a formula containing about 1.6 g of protein/100 kcal as
compared to control formulae containing 2.15 or 2.70 g of protein/100 kcal or the breastfed
reference group.
Therefore, the Panel concludes that the use of FOF with a protein content of at least 1.6 g/100 kcal
from intact cow’s milk protein otherwise complying with the requirements of relevant EU legislation is
safe and suitable for healthy infants living in Europe with an intake of complementary foods of a
sufficient quality. This conclusion does not apply to IF.
4.2. On the safety and suitability for use by infants of FOF with a protein
content of at least 1.6 g/100 kcal from intact goat’s milk protein,
soy protein isolates or protein hydrolysates otherwise complying
with the requirements of relevant EU legislation
On the basis of:
a) a previous evaluation by the Panel on the safety and suitability of goat’s milk protein as a
source of protein in IF and FOF (EFSA NDA Panel, 2012b), and
b) the Panel’s conclusions regarding the safety and suitability of FOF with a protein content of at
least 1.6 g/100 kcal from intact cow’s milk protein otherwise complying with the requirements
of relevant EU legislation (Section 4.1),
the Panel concludes that the use of FOF with a protein content of at least 1.6 g/100 kcal from intact
goat’s milk protein otherwise complying with the requirements of relevant EU legislation is safe and
suitable for healthy infants living in Europe with an intake of complementary foods of a sufficient
quality. This conclusion does not apply to IF.
The Panel considers, however, that the safety and suitability of each FOF (and IF) manufactured
from protein hydrolysates have to be established by clinical evaluation in the target population (EFSA
NDA Panel, 2014). The Panel also considers that, given the higher minimum protein requirements
established for FOF (and IF) manufactured from soy protein isolates (i.e. 2.25 g/100 kcal) and the lack
of data available on the use of FOF from soy protein isolates in the target population, additional
studies are required to establish the safety and suitability of FOF manufactured from soy protein
isolates with a protein content of at least 1.6 g/100 kcal. Therefore, the Panel concludes that the
safety and suitability of FOF with a protein content of at least 1.6 g/100 kcal manufactured from either
protein hydrolysates or soy protein isolates cannot be established with the available data. The same
conclusion applies to IF.
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Application for the placing on the market of a follow-on formula with a new minimum protein
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